Evidence map›Paper›PMID 34903599›Full record

ArticleCancer research2022

Mammary Tumor-Derived Transplants as Breast Cancer Models to Evaluate Tumor-Immune Interactions and Therapeutic Responses.

Jade Moore, Lin Ma, Ann A Lazar, Mary Helen Barcellos-Hoff

Open access · bronzeAbstract read
In one paragraph

Article in Cancer research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Jade MooreDepartment of Radiation Oncology and Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California.ORCID 0000-0001-8092-3363
Lin MaDepartment of Radiation Oncology and Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California.
Ann A LazarDepartment of Oral Epidemiology, School of Dentistry, University of California San Francisco, San Francisco, California.
Mary Helen Barcellos-HoffDepartment of Radiation Oncology and Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California. maryhelen.barcellos-hoff@ucsf.edu.ORCID 0000-0002-5994-9558
UCSF Helen Diller Family Comprehensive Cancer Center · USUniversity of California, San Francisco · US

Funding

Molecular and Cellular Mechanisms in CancerT32CA108462 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GOGA, ANDREI · 2004 to 2024
$10.4M
Contribution of development and age to breast cancer etiologyR01CA190980 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BARCELLOS-HOFF, MARY HELEN · 2015 to 2020
$2.6M
Definition of Immune Infiltrate Phenotype and DNA Damage Response Deficits Across Diverse Murine Mammary CarcinomasR01CA239235 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BARCELLOS-HOFF, MARY HELEN · 2019 to 2023
$2.5M
NCI NIH HHS R01 CA190980NCI NIH HHS R01 CA239235NCI NIH HHS T32 CA108462
6 · The paper itself

Abstract

In breast cancer, the type and distribution of infiltrating immune cells are associated with clinical outcome. Moreover, cancers with abundant tumor-infiltrating lymphocytes (TIL) are more likely to respond to immunotherapy, whereas those in which CD8

Indexed as

AnimalsBreast NeoplasmsDisease Models, AnimalFemaleLymphocytes, Tumor-InfiltratingMammary Neoplasms, AnimalMiceMice, NudeTumor Microenvironment

Identifiers

PMID34903599
PMCPMC8813892
OpenAlexW4200060415

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.